Download biographical sketch - Chao Family Comprehensive Cancer Center

Principal Investigator/Program Director (last, First, Middle):
Meyskens, Frank L.
5P30CA062203-17
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Meyskens Jr., Frank L.
Professor of Medicine, Biological Chemistry, and
Public Health
eRA COMMONS USER NAME (credential, e.g., agency login)
FLMEYSKENS
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
University of California, San Francisco, CA
University of California, San Francisco, CA
House Staff Training (Interim First Year
Resident), University of California Moffet
Hospital, San Francisco, CA
Clinical Associate, Medicine Branch, NCI,
Bethesda
Clinical Associate, Laboratory of Tumor Cell
Biology, NCI, Bethesda, MD
B.S.
M.D.
06/67
06/72
Biology
Medicine
06/72-06/74
06/74-06/75
06/75-06/77
A. Personal Statement
I am dedicated to the development, direction, planning, implementation, and evaluation of the research and
clinical activities of the Cancer Center. I am responsible for the establishment of administrative, programmatic,
and scientific infrastructure to assure effective development of multidisciplinary-oriented interdisciplinary, interprogrammatic, and transdisciplinary cancer research. I have been conducting basic and clinical research
involving human melanoma since 1978. In the past 15 years I have been a leader in the investigation of redox
regulation of transcriptional factors in this disease. In the past 5 years we have focused on mechanistic studies
of NOS/NO as a basis for the development of therapeutic prevention and treatment of this cancer. This
application emphasizes experimental therapeutics involving the natural nutrients resveratrol (see publications #
5,6,12 below) and curcumin as NO scavengers at the animal level. It is a logical evolution of our previous work
and also takes advantage of an enormous expertise at UC Irvine related to NOS. Also, we have just completed
phase I/II marker studies of both resveratrol and curcumin at UCI through our NCI-funded Phase I and II
chemoprevention consortium (F Meyskens, P.I.). We are also positioned to bring our results to clinical trial in
melanoma specifically as we have a large Pigmented Lesion Clinic, where we see over 250 new patients with
early melanomas per year, and have an active trials program that spans the continuum from prevention (A
randomized trial of Lovastatin in patients with dysplastic nevi) to treatment of metastatic disease (several
phase II and a phase I trial). Additionally, I oversee Prevention and Control Research of SWOG as its
Associate Chair, so expansion to a larger venue for phase III trials would also be facilitated. I have been
involved in the mentoring of undergraduate, graduate students, research and clinical post docs and young
investigators for 35 years including many budding repurposed physician scientists in the evolving field of
cancer prevention and control (details Section 2.0). This work has been funded by the NIH/NCI up to this date
by R01’s, U01’s, PPG and contracts. I have been involved and P.I. of multiple treatment and prevention phase
II and III trials over the past 30 years. My lab is active and fully equipped for modern molecular research and
has been funded by a mixture of ACS, Foundations and grateful patients.
B. Positions and Honors
Positions and Employment
1977-1981
1984-1989
1984-1989
Assistant Professor of Medicine (Hematology Oncology), University of Arizona, Tucson, AZ
Associate Professor of Molecular and Cell Biology, University of Arizona, Tucson, AZ
Director for Cancer Prevention and Control, Arizona Cancer Center, Tucson, AZ
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (last, First, Middle):
1985-1989
19891999-2004
2004-2007
2007-2009
Meyskens, Frank L.
5P30CA062203-17
Professor of Medicine (Hematology Oncology), University of Arizona, Tucson, AZ
Professor of Medicine and Biological Chemistry; Director, Chao Family Comprehensive Cancer
Center, University of California, Irvine, Irvine, CA
Associate Dean of Research, College of Medicine, University of California, Irvine, Irvine, CA
Senior Associate Dean of Health Sciences, University of California, Irvine, Irvine, CA
Associate Vice Chancellor of Health Sciences, University of California, Irvine, Irvine, CA
Other Experience and Professional Memberships
1974Board Certified, Internal Medicine, American Board of Internal Medicine
1982Board Certified, Oncology, American Board of Internal Medicine
1982
Co-Chair, 1st, 2nd, 3rd and 4th International Conferences on Modulation and Mediation of
Cancer by Vitamins, Tucson, AZ
1985
Co-Chair, 1st, 2nd, 3rd and 4th International Conferences on Modulation and Mediation of
Cancer by Vitamins, Tucson, AZ
1988
Co-Chair, 1st, 2nd, 3rd and 4th International Conferences on Modulation and Mediation of
Cancer by Vitamins, Tucson, AZ
1992
Co-Chair, 1st, 2nd, 3rd and 4th International Conferences on Modulation and Mediation of
Cancer by Vitamins, Tucson, AZ
1986-1990
Board of Scientific Counselors (Chair, 1990), DCPC, NCI
1997-2004
President, International Society of Chemoprevention
2007-2010
President, Pam American Society for Pigment Cell Research
2007 Associate Chair of Cancer Control and Prevention, SWOG
Honors
1968
1989
1990
2006
2006
2008
2009
Dean’s Prize in Research, University of California, San Francisco, CA
Grace A. Goldsmith Award, American College of Nutrition
NCI – Year 2000 Award
Inaugural Salmon Awardee in Translational Research, Arizona Cancer Center
Distinguished Career Achievement Award, American Society of Preventive Oncology
AACR Cancer Prevent Awardee
Elected to Royal Society of Medicine (Oversees Fellow)
C. Selected peer-reviewed publications (in chronological order)
Most relevant to the current application
1. Linden, K.G., Carpenter, P.M., McLaren, C.E., Barr, R.J., Hite, P., Sun, J.D., Li, K.T., Viner, J.L.,
Meyskens, F.L. Jr. (2003). Chemoprevention of Nonmelanoma a Skin cancer: Experience with a
Polyphenol from Green Tea. Recent Results in Cancer Research, Vol 163, p165-171. PMID: 12903852
2. Zell, J., Meyskens, F.L. Jr. (2008). Cancer Prevention, Screening and early detection. In Abeloff M et al
Clinical Oncology, 4th edition, also editions 2, 3.
3. Hansen, L.K., Feigl, P., Modiano, M.R., Lopez, J.A., Sluder, S.E., Moinpour, C.M., Pauler, D.K., Meyskens,
F.L., Jr. (2005). An educational program to increase cervical and breast cancer screening in Hispanic
Women. Cancer Nursing, 28(1):47-53. PMID: 15681982
4. Meyskens, F.L. Jr, Szabo, E. (June 2005). Diet and cancer: The disconnect between epidemiology and
randomized clinical trials. Cancer Epidemiol Prev Biom., 14(6):1366-0. PMID: 15941942
5 Meyskens, F.L. Jr., Ransohoff, D.F. (Aug 2006). Predicting risk for the appearance of melanoma. J Clin
Oncol., 1;24(22):3522-3. PMID: 16728487
Additional recent publications of importance to the field (in chronological order)
1. Meyskens, F.L. Jr. (2006). American Society of Preventive Oncology Distinguished Career Achievement
Lecture - Enjoy the journey: the long and winding road of chemoprevention agent development. Cancer
Epid Prev. Bio. PMID: 17119025
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (last, First, Middle):
Meyskens, Frank L.
5P30CA062203-17
2. Meyskens, F.L. Jr., McLaren, C.E., Pelot, D., Fujikawa-Brooks, S., Carpenter, P.M., Hawk, E., Kelloff, G.,
Lawson, M.J., Kidao, J., McCracken, J., Albers, C.G., Ahnen, D.J., Turgeon, D.K., Goldschmid, S., Lance,
P., Hagaedorn, C.H., Gillen, D.L., Gerner, E.W. (2008 Jun). Difluoromethylornithine plus sulindac for the
prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer
rev Res, (Phila. Pa). 1(1):32-8. PMID: 18841250
3. Lippman, S.M., Klein, E.A., Goodman, P.J., Meyskens, F.L. Jr., Baker, L.H., Coltman, C.A. Jr. (2009 Jan).
Effect of selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 7;301(1):39-51. Epub 2008
Dec 9. PMID: 19066370
4. Goodman, G.E., Alberts, D.S., Meyskens, F.L. Jr. (2008 Dec). Retinol, vitamins, and cancer prevention: 25
years of learning and relearning. J Clin Oncol., 1;26934:5495-6. PMID: 18981460
5. Gerner, E.W., Meyskens, F.L. Jr. (2009 Feb). Combination chemoprevention for colon cancer targeting
polyamine synthesis and inflammation. Clin Cancer Res. 1;15(3):758-61. PMID: 19188144
6. Yang, S., Meyskens, F.L., Jr. (2009 2008 Aug 20). Apurinic/apyrimidinic endonuclease /redox effector
factor-1(APE/Ref-1) a unique target for the prevention and treatment of human melanoma. Antioxid Redox
Signal, 11:639-650. [Epub ahead of print]PMID: 18715151 [PubMed – as supplied by publisher].
7. Yang, Z., Yang, S., Misner, B.J., Chiu, R., Liu, F., Meyskens, F.L. Jr. (2008 Dec). Nitric oxide initiates
progression of human melanoma via a feedback loop medited by apurinic/apyrimidinic endonuclease1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther., 7(12):3751-60. PMID: 19074850
8. Zell, J.A., McLaren, C.E., Chen, W.P., Thompson, P.A., Gerner, E.W., Meyskens, F.L. (2010 Oct).
Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes
among colorectal adenoma patients. J Natl Cancer Inst., 6;102(19):1513-6. Epub 2010 Aug 26 PubMed
PMID:30798393.
9. Meyskens, F.L. Jr., Curt, G.A., Brenner, D.E., Gordon, G., Heberman, R.B., Finn, O., Kelloff, G.J., Khleif,
S.N., Sigman, C.C., Szabo, E. for the C-Change Chemoprevention Clinical Trials and Biomarkers
Subcommittee. Regulatory Approval of Cancer Risk-reducing (Chemopreventive) Drugs: Moving What We
Have Learned into the Clinic. Cancer Prev Res. In press 2011 (February).
10. Meyskens, F.L. Jr., McLaren, C.E. (2010 Dec 15). Chemoprevention, risk reduction, therapeutic
prevention, or preventive therapy? J Natl Cancer Inst., 102(24):1815-7. Epub 2010 Nov 29. PMID:
21115881
D. Research Support
Ongoing Research Support
5P30CA062203-16 (Meyskens)
02/01/09-01/31/14
NIH/NCI
University of California Irvine Cancer Center Support Grant Infrastructure and Research award to support
cancer research at UC Irvine and beyond.
Role: PI
F021095
(Meyskens)
06/01/07-05/31/17
SWOG- Associate Chair for Cancer Control and Prevention
Serve as co-P.I of DCL grant and is ultimately responsible for the fiscal and scientific oversight and integrity of
the proposed project. He will develop and drive the scientific agenda for cancer prevention and control and
make decisions in keeping with the overall priorities of the Group.
Role: PI
5 N01 CN35160-5
(Meyskens)
10/01/03-09/29/12
NIH/NCI
Phase I and Phase II Clinical Trials of Chemopreventive Agents
The overall objective of this project is to conduct multiple early phase (Phase I and Phase II) clinical trials for
candidate cancer preventive agents using the extant infrastructure that has been developed over the past
decade at the UCI NCI-designated Chao Family Comprehensive Cancer Center. The main focus of these trials
is to assess the cancer preventive potential of various compounds by evaluating their effects on biological or
imaging endpoints.
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (last, First, Middle):
Meyskens, Frank L.
5P30CA062203-17
Role: PI
Completed Research Support
5 R01 CA088078-05 Meyskens (PI)
09/30/02-08/31/10
NIH/NCI
Phase III Colon Cancer Prevention Trial
The long-range objective of our work is to develop safe and effective drugs to prevent colon cancer, which is
the fourth most common incident cancer in America with over 58,000 people dying of the disease in the year
2000. This trial was completed and reported in 2008 and patients are now in long term follow-up.
Role: PI
5 U01 CA072294-11 Meyskens (PI)
08/31/04-08/31/11
NIH/NCI
Bowman-Birk Inhibitor and Oral Leukoplakia
To conduct phase IIa and IIb chemoprevention studies of BBIC in oral leukoplakia. Phase IIa was completed in
9/98 and a randomized phase IIb trial started in 10/00 which was completed in April 2010. The study results
are being analyzed and will be reported later this year.
Role: PI
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page